Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma

Video

Naresh Bumma, MD, details other bispecific agents on the horizon for relapsed multiple myeloma treatment.

Related Videos
A panel of 4 experts on multiple myeloma
Beth Faiman, CNP, PhD, an expert on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Surbhi Sidana, MD, an expert on multiple myeloma
Related Content